FindTrial
Sign In

Safety and clinical effcet of irreversible electroporation ablation therapy for renal malignant tumor

Safety and clinical effcet of irreversible electroporation ablation therapy for renal malignant tumor

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17012470
Enrollment
Unknown
Registered
2017-08-25
Start date
2017-06-14
Completion date
Unknown
Last updated
2017-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal malignant tumor

Interventions

1:irreversible electroporation ablation therapy

Sponsors

Ruijin Hospital Luwan Branch, School of Medicine, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) unrescetable renal malignant tumor; (2) the expected survival time more than 3 months; (3) Karnofsky Performance Scale (KPS) >60; (4) willingness and ability to comply with the study.

Exclusion criteria

Exclusion criteria: 1. severe coagulation defect; 2. can not tolerate general anesthesia; 3. can not be completely ablation preoperative evaluation; 4. severe cardiopulmonary function or hepatic renal dysfunction; 5. presence of cardiac pacemaker.

Design outcomes

Primary

MeasureTime frame
Hemodynamics in the operation;Postoperative side effect;Postoperative image examination;treatment parameter;—

Countries

China

Contacts

Public ContactZhongmin Wang

Ruijin Hospital Luwan Branch, School of Medicine, Shanghai Jiaotong University

wzm0722@hotmail.com+86 13901848333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026